Adtalem Global Education Reaffirmed Its 2026 Guidance With Revenue Of $1.9B-$1.94B Vs. Consensus Of $1.924B Or Approximately 6.0%-8.5% Growth YoY, And Adjusted EPS Of $7.60 To $7.90 Vs. $7.785 Est.

Adtalem Global Education Inc. (NYSE:ATGE), the largest healthcare educator in the United States, today announced plans to accelerate execution against its remaining $136 million balance under its existing $150 million board authorized share repurchase program1, reflecting its current financial strength through revenue and profit growth as well as confidence in the Company's long-term outlook.

"Adtalem's Board of Directors and management remain confident in the Company's strategic position and long-term outlook. We continue to deliver strong results—with total enrollment increasing 8% year-over-year and revenue up 10.8% year-over-year for the first quarter. Industry trends around healthcare workforce development also remain highly favorable," said Steve Beard, chairman and chief executive officer, Adtalem Global Education. "Accelerating our share repurchase activity underscores our conviction in our strategy, and current market prices present an attractive use of capital."

The Company reaffirmed its guidance for fiscal year 2026, with revenue expected to be in the range of $1,900 million to $1,940 million or approximately 6.0% to 8.5% growth year-over-year, and adjusted earnings per share anticipated to be in the range of $7.60 to $7.90, or approximately 14.0% to 18.5% growth year-over-year.